China approves its first mRNA vaccine, from domestic drugmaker CSPC
I'm PortAI, I can summarize articles.
China's CSPC Pharmaceutical Group has become the first company in the country to receive emergency use authorisation for its mRNA COVID-19 vaccine. The vaccine has been independently developed and demonstrated a low incidence of adverse effects, particularly in the elderly. The vaccine targets major Omicron coronavirus variants and has been approved for use even as COVID-19 cases in the country decline after a recent surge. While vaccines available in China are considered less effective than global alternatives like Moderna and Pfizer-BioNTech, Chinese authorities have declined to use foreign mRNA vaccines.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments